Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05203367
Other study ID # BLCL-BAR-502-101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date November 25, 2022
Est. completion date March 30, 2023

Study information

Verified date August 2022
Source BAR Pharmaceuticals s.r.l.
Contact Marlene Fonseca, MD
Phone +351220959020
Email mfonseca@blueclinical.pt
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female subjects.


Description:

This clinical trial will be the first-in-Human (FiH) study of BAR 502. This study is planned to investigate up to 4 dose levels of BAR 502. Each dose level will consist of 8 healthy male and female subjects (ratio 1:1, male: female) to have 6 subjects being administered BAR 502 and 2 subjects being administered placebo (ratio 3:1, active: placebo). The study is designed to meet the following objectives: - Primary: - To evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female subjects. - Secondary: - To investigate the pharmacokinetics (PK) of single-ascending doses of BAR 502 in healthy male and female subjects; - To investigate the pharmacodynamics (PD) of single-ascending doses of BAR 502 in healthy male and female subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date March 30, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Signed informed consent in a language understandable to the subject prior to any study-mandated procedure. 2. Ability to communicate well with the investigator, and to understand and comply with the study requirements. 3. Healthy male or female subject aged between 18 and 55 years (inclusive) at Screening. 4. Body mass index (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at Screening. 5. Systolic blood pressure (SBP) 90-140 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on same arm after =5 min in the seated position, at Screening. 6. Estimated glomerular filtration rate calculated using the Cockcroft-Gault equation and normalized to an average surface area of 1.73 m2 = 90 mL/min at Screening. 7. If woman, she meets one of the following criteria: 1. is of non-childbearing potential; or 2. is of childbearing potential and agrees to use an accepted non-hormonal or hormonal contraceptive method. If man, he is infertile, vasectomized (i.e. who has received medical assessment of the surgical success) or agrees to abstain from or to use a condom during heterosexual intercourse with a woman of childbearing potential or a pregnant woman, and agrees not to donate sperm, from investigational product administration until at least 90 days after the investigational product administration. In addition, the subject must ensure that his female partner of childbearing potential agrees to consistently and correctly use one of the acceptable contraceptive methods mentioned above, for the same period of time. Exclusion Criteria: - At screening: 1. Previous exposure to BAR 502. 2. Known hypersensitivity to BAR 502, or any of its excipients. 3. Clinically relevant findings on physical examination. 4. Clinically relevant abnormalities on 12-lead ECG, measured after 5 min in a supine position. 5. Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis). 6. QTcF > 450 ms in males and > 470 ms in females. 7. Medical history and/or clinical or laboratory evidence of liver or hepatobiliary disease or liver injury as indicated by serum alanine aminotransferase (ALT), AST, gamma-glutamyl transferase (GGT), ALP or total bilirubin levels exceeding the upper limit of normal (ULN). 8. International Normalized Ratio (INR) > 1.2. 9. Any medical condition, acute, ongoing, recurrent or chronic, that presents a potential risk to the participant and/or that may compromise the objectives of the study. 10. History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the distribution, metabolism, or excretion of the investigational product. 11. History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to Screening. 12. Previous clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions. 13. Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access, or puncture, veins with a tendency to rupture during or after puncture). 14. Participation in a clinical study involving investigational product administration within 3 months prior to Screening or in more than 2 clinical studies within 1 year prior to Screening. 15. Excessive methylxanthines consumption, defined as = 800 mg per day. 16. Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) within 3 months prior to Screening and inability to refrain from nicotine intake from Screening up to End-of-Study (EOS). 17. Loss of 250 mL or more of blood within 3 months prior to Screening. 18. Positive hepatitis B surface antigen (HBsAg) and/or hepatitis C virus antibodies. 19. Positive human immunodeficiency virus (HIV1 and HIV2) antibodies. 20. Positive results in urine drugs-of-abuse, cotinine or ethanol tests. 21. If woman, she is breastfeeding. 22. Positive result in serum pregnancy test. 23. Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol or may render the subject unsuitable for the study. - At admission to treatment period: 24. Positive or inconclusive SARS-CoV-2 test result using polymerase chain reaction (PCR) technology prior to Admission to the clinical site. 25. Any recent disease or condition or treatment that, according to the Investigator, would put the subject at undue risk due to study participation or occurred at a timeframe in which may interfere with the study outcomes. 26. Clinically relevant findings on physical examination. 27. Clinically relevant abnormalities on 12-lead ECG, measured after 5 min in a supine position. 28. Clinically relevant findings in clinical laboratory tests. 29. Use of prescription or nonprescription medicinal products, including vitamins, food supplements, herbal supplements (including St John's Wort), within 3 weeks prior to study treatment administration, unless in the Investigator's opinion the medication does not interfere with the pharmacokinetics of study drug or compromise subject safety. 30. Consumption of Seville oranges, pomelo, pomegranate, starfruit or grapefruit products (fresh, canned, or frozen) since Screening. 31. Positive result in urine drugs-of-abuse, cotinine or ethanol tests. 32. Positive result in urine pregnancy test. 33. Any other condition that the investigator considers to render the subject unsuitable for the treatment period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BAR502
Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours. BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg).
Placebo
Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment

Locations

Country Name City State
Portugal BlueClinical Phase I Porto

Sponsors (1)

Lead Sponsor Collaborator
BAR Pharmaceuticals s.r.l.

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events Safety will be evaluated through the assessment of adverse events Through study completion, an average of 2 months
Primary Assessment of physical examination Safety will be evaluated through the assessment of physical examination, which will include: general appearance; skin; head and neck; thorax and abdomen; pulmonary auscultation; cardiac auscultation; abdomen palpation; limbs. At screening (Day -21 to Day -3 for male and female subjects of non-childbearing potential, Day -28 to Day -7 for female subjects of childbearing potential) and end of study ( Day 8)
Primary Assessment of 12-lead electrocardiogram Safety will be evaluated through the assessment of 12-lead ECG. The following variables are to be collected on the eCRF: HR (bpm), and the intervals PR (ms), QRS (ms), QT (ms), QTcB (ms) and QTcF (ms). At screening (Day -21 to Day -3 for male and female subjects of non-childbearing potential, Day -28 to Day -7 for female subjects of childbearing potential), admission (Day-1), and from day 1 to day 4 of the study
Primary Change from baseline at each time point of measurement in supine blood pressure (both systolic and diastolic) Safety will be evaluated through the assessment of vital signs (systolic and diastolic blood pressure) At screening (Day -21 to Day -3 for male and female subjects of non-childbearing potential, Day -28 to Day -7 for female subjects of childbearing potential), admission (Day -1), from Day 1 to Day 4 of the study, and at end of study (at Day 8).
Primary Change from baseline at each time point of measurement in pulse rate Safety will be evaluated through the assessment of vital signs At screening (Day -21 to Day -3 for male and female subjects of non-childbearing potential, Day -28 to Day -7 for female subjects of childbearing potential), admission (Day -1), from day 1 to day 4 of the study, and at end of study (at Day 8)..
Secondary Maximum concentration (Cmax) Determination of BAR 502 concentrations in plasma, to investigate the pharmacokinetics Within 1 hour prior to treatment administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 74 hours after treatment administration.
Secondary Time of occurrence of Cmax (Tmax) Determination of BAR 502 concentrations in plasma, to investigate the pharmacokinetics Within 1 hour prior to treatment administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 74 hours after treatment administration.
Secondary Area under the plasma concentration-time curve (AUC) from time zero to last sampling time with quantifiable concentrations (AUC0-t); Determination of BAR 502 concentrations in plasma, to investigate the pharmacokinetics Within 1 hour prior to treatment administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 74 hours after treatment administration.
Secondary AUC extrapolated to infinity Determination of BAR 502 concentrations in plasma, to investigate the pharmacokinetics Within 1 hour prior to treatment administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 74 hours after treatment administration.
Secondary Apparent terminal elimination rate constant (?z); and apparent terminal elimination half-life (t1/2) Determination of BAR 502 concentrations in plasma to investigate the pharmacokinetics Within 1 hour prior to treatment administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 74 hours after treatment administration.
Secondary Cumulative amount of drug excreted in urine (AmtCUM) Determination of BAR 502 concentrations in urine to investigate the pharmacokinetics From treatment administration to day 4 of the study
Secondary Area under the urine excretion curve (AUR) from time zero to last observed concentration (AURClast) Determination of BAR 502 concentrations in urine to investigate the pharmacokinetics From treatment administration to day 4 of the study
Secondary Maximum rate of urinary excretion (Rmax) Determination of BAR 502 concentrations in urine to investigate the pharmacokinetics From treatment administration to day 4 of the study
Secondary Percentage of drug recovered in urine (REC%) Determination of BAR 502 concentrations in urine to investigate the pharmacokinetics From treatment administration to day 4 of the study
Secondary Time to Rmax (tumax) Determination of BAR 502 concentrations in urine to investigate the pharmacokinetics From treatment administration to day 4 of the study
Secondary Renal clearance (CLR) Determination of BAR 502 concentrations in urine to investigate the pharmacokinetics From treatment administration to day 4 of the study
Secondary Serum concentrations of total bile acids over time up to 24 hours post-dose To investigate the pharmacodynamics At admission, within 1 hour prior to study treatment administration, and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 16 and 24 hours after treatment administration.
Secondary Serum concentrations of FGF19 over time up to 24 hours post-dose. To investigate the pharmacodynamics (biomarkers of Farnesoid X Receptor (FXR) target engagement) At admission, within 1 hour prior to study treatment administration, and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 16 and 24 hours after treatment administration
Secondary Serum concentrations of C4 over time up to 24 hours post-dose. To investigate the pharmacodynamics (biomarkers of Farnesoid X Receptor (FXR) target engagement) At admission, within 1 hour prior to study treatment administration, and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 16 and 24 hours after treatment administration
Secondary Serum concentrations of GLP-1 over time up to 24 hours post-dose. To investigate the pharmacodynamics (marker of G protein-coupled bile acid-activated receptor 1 (GPBAR1) activation) At admission, within 1 hour prior to study treatment administration, and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 16 and 24 hours after treatment administration
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects With Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4